92 related articles for article (PubMed ID: 19797353)
41. KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance.
Miglio U; Oldani A; Mezzapelle R; Veggiani C; Paganotti A; Garavoglia M; Boldorini R
Pathol Res Pract; 2014 May; 210(5):307-11. PubMed ID: 24629489
[TBL] [Abstract][Full Text] [Related]
42. Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma.
Porta M; Pumarega J; Amaral AFS; Genkinger JM; Camargo J; Mucci L; Alguacil J; Gasull M; Zhang X; Morales E; Iglesias M; Ogino S; Engel LS;
Environ Res; 2020 Nov; 190():109781. PubMed ID: 32791343
[TBL] [Abstract][Full Text] [Related]
43. Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.
Wang Z; Zhang C; Nagee K; Mohammadi A; Monteiro C
Pancreas; 2016 Mar; 45(3):337-41. PubMed ID: 26474433
[TBL] [Abstract][Full Text] [Related]
44. An Oncogenic
Shimada Y; Kohno T; Ueno H; Ino Y; Hayashi H; Nakaoku T; Sakamoto Y; Kondo S; Morizane C; Shimada K; Okusaka T; Hiraoka N
Oncologist; 2017 Feb; 22(2):158-164. PubMed ID: 28167572
[TBL] [Abstract][Full Text] [Related]
45. Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group.
Porta M; Malats N; Guarner L; Carrato A; Rifà J; Salas A; Corominas JM; Andreu M; Real FX
J Epidemiol Community Health; 1999 Nov; 53(11):702-9. PubMed ID: 10656099
[TBL] [Abstract][Full Text] [Related]
46. KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma.
Bittoni A; Piva F; Santoni M; Andrikou K; Conti A; Loretelli C; Mandolesi A; Lanese A; Pellei C; Scarpelli M; Principato G; Cascinu S
Future Oncol; 2015; 11(13):1905-17. PubMed ID: 26161927
[TBL] [Abstract][Full Text] [Related]
47. Influence of tumor stage, symptoms, and time of blood draw on serum concentrations of organochlorine compounds in exocrine pancreatic cancer.
Porta M; Pumarega J; López T; Jariod M; Marco E; Grimalt JO;
Cancer Causes Control; 2009 Dec; 20(10):1893-906. PubMed ID: 19562493
[TBL] [Abstract][Full Text] [Related]
48. Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40.
Bergmann F; Aulmann S; Wente MN; Penzel R; Esposito I; Kleeff J; Friess H; Schirmacher P
J Clin Pathol; 2006 Jun; 59(6):580-4. PubMed ID: 16497872
[TBL] [Abstract][Full Text] [Related]
49. Relationships between occupational history and serum concentrations of organochlorine compounds in exocrine pancreatic cancer.
Bosch de Basea M; Porta M; Alguacil J; Puigdomènech E; Gasull M; Garrido JA; López T;
Occup Environ Med; 2011 May; 68(5):332-8. PubMed ID: 21098829
[TBL] [Abstract][Full Text] [Related]
50. CYP1B1 polymorphisms and k-ras mutations in patients with pancreatic ductal adenocarcinoma.
Crous-Bou M; De Vivo I; Porta M; Pumarega JA; López T; Alguacil J; Morales E; Malats N; Rifà J; Hunter DJ; Real FX;
Dig Dis Sci; 2008 May; 53(5):1417-21. PubMed ID: 18347981
[TBL] [Abstract][Full Text] [Related]
51. Kras, Pten, NF-κB, and inflammation: dangerous liaisons.
Chiao PJ; Ling J
Cancer Discov; 2011 Jul; 1(2):103-5. PubMed ID: 22586351
[TBL] [Abstract][Full Text] [Related]
52. Food and nutrient intakes and K-ras mutations in exocrine pancreatic cancer.
Morales E; Porta M; Vioque J; López T; Mendez MA; Pumarega J; Malats N; Crous-Bou M; Ngo J; Rifà J; Carrato A; Guarner L; Corominas JM; Real FX;
J Epidemiol Community Health; 2007 Jul; 61(7):641-9. PubMed ID: 17568059
[TBL] [Abstract][Full Text] [Related]
53. Ultrasensitive plasma ctDNA
Chen I; Raymond VM; Geis JA; Collisson EA; Jensen BV; Hermann KL; Erlander MG; Tempero M; Johansen JS
Oncotarget; 2017 Nov; 8(58):97769-97786. PubMed ID: 29228650
[TBL] [Abstract][Full Text] [Related]
54. Role of organochlorine compounds in the etiology of pancreatic cancer: a proposal to develop methodological standards.
Porta M
Epidemiology; 2001 Mar; 12(2):272-6. PubMed ID: 11246593
[TBL] [Abstract][Full Text] [Related]
55. Genetics of Pancreatic Cancer and Its Implications on Therapy.
Tatarian T; Winter JM
Surg Clin North Am; 2016 Dec; 96(6):1207-1221. PubMed ID: 27865273
[TBL] [Abstract][Full Text] [Related]
56. The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure.
Lomberk GA; Urrutia R
Surg Clin North Am; 2015 Oct; 95(5):935-52. PubMed ID: 26315515
[TBL] [Abstract][Full Text] [Related]
57. Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules.
Basseville A; Bates S; Fojo T
Nat Rev Clin Oncol; 2015 Aug; 12(8):442-4. PubMed ID: 26169922
[No Abstract] [Full Text] [Related]
58. Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?
Sheel A; Addison S; Nuguru SP; Manne A
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884515
[TBL] [Abstract][Full Text] [Related]
59. Simultaneous cancer of the pancreas occurring in husband and wife.
Ferguson LJ; Watts JM
Gut; 1980 Jun; 21(6):537-40. PubMed ID: 7429316
[TBL] [Abstract][Full Text] [Related]
60. Exposures, mutations and the history of causality.
Vineis P
J Epidemiol Community Health; 2000 Sep; 54(9):652-3. PubMed ID: 10942441
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
